Conigliaro and colleagues tested palmitoylethanolamide in the compression of the median nerve in the wrist, the carpal tunnel syndrome. The dosed 1200 mg/day and 600 mg/day and compared patients recieving PEA to others, with comparable complaints, as control patients.
PEA treatment significantly improved the CTS-induced reduction of median nerve latency time (P<0.0004); PEA effect was dose-dependent. Tinel's sign presence and symptoms of discomfort such as tingling and pain were also reduced. 1200 mg PEA/day seems the best dosage. This can be obtained by een PEA-houdend product 600 mg twice daily or 1200 mg PeaPure, dosed either 800 mg/morning 400 mg/evening or reverse. We prefer 800 mg in the eventing, as most symptoms occur nights.
This was not a well controlled study.
In Riccione, at a neurological congress 2011 however, details of a clinical trial including 40 patients suffering from CTS, painscore around 8, treated for 60 days with 1200 mg PEA/daily. The control group were not treated. Pain in the control group intensivied during these 2 months, up to a painscore of 9. The patients treated with PEA found relief of pain, up to a painscore of 6.5, the difference was statistically different. More importantly, the electrophysiological measurements showed normalisation of the function of the entrapped nerve.
Source: Minerva Med. 2011 Apr;102(2):141-7.
Use of palmitoylethanolamide in the entrapment neuropathy of the median in the wrist. by Conigliaro R, Drago V, Foster PS, Schievano C, Di Marzo V.